Sleep Alterations in Treatment-resistant Depression Patients Undergoing Ketamine Treatment

Overview

Journal Pharmacol Rep

Specialty Pharmacology

Date 2024 Aug 29

PMID 39207673

Authors

Aleksander Kwasny

Wieslaw Jerzy Cubala

Adam Wlodarczyk

Krzysztof Pastuszak

Affiliations

Soon will be listed here.

Abstract

Background: This study examines self-reported sleep alterations in treatment-resistant depression (TRD) inpatients following intravenous ketamine administration.

Methods: This is a post-hoc analysis of a naturalistic observational study, which enrolled 28 inpatients with treatment-resistant major depressive disorder and analyzed self-reported sleep changes (items 1-4; 'insomnia', 'nighttime restlessness', 'early morning waking', 'hypersomnia') in Inventory of Depressive Symptomatology 30-item (IDS SR-30) in responders and non-responders stratified per Montgomery-Åsberg Depression Rating Scale (MADRS) during short-term ketamine treatment.

Results: Responders, as well as non-responders, did not experience significant changes in IDS SR-30 sleep items ('insomnia', 'nighttime restlessness', 'early morning waking', 'hypersomnia') (p's > 0.05) at 7-day follow-up after eight intravenous ketamine infusions as compared to baseline.

Conclusion: Neither responders, nor non-responders reported any significant alterations in sleep patterns during ketamine infusions. These findings are not in line with current literature, as so far modest improvements in sleep during ketamine treatment have been reported. Results should be interpreted with caution, primarily due to the small sample size.

References

Jauhar S, Morrison P . Esketamine for treatment resistant depression. BMJ. 2019; 366:l5572. DOI: 10.1136/bmj.l5572. View

Zarate Jr C, Singh J, Carlson P, Brutsche N, Ameli R, Luckenbaugh D . A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006; 63(8):856-64. DOI: 10.1001/archpsyc.63.8.856. View

Burgdorf J, Vitaterna M, Olker C, Song E, Christian E, Sorensen L . NMDAR activation regulates the daily rhythms of sleep and mood. Sleep. 2019; 42(10). PMC: 6783887. DOI: 10.1093/sleep/zsz135. View

Bernert R, Turvey C, Conwell Y, Joiner Jr T . Association of poor subjective sleep quality with risk for death by suicide during a 10-year period: a longitudinal, population-based study of late life. JAMA Psychiatry. 2014; 71(10):1129-37. PMC: 4283786. DOI: 10.1001/jamapsychiatry.2014.1126. View

Geoffroy P, Hoertel N, Etain B, Bellivier F, Delorme R, Limosin F . Insomnia and hypersomnia in major depressive episode: Prevalence, sociodemographic characteristics and psychiatric comorbidity in a population-based study. J Affect Disord. 2017; 226:132-141. DOI: 10.1016/j.jad.2017.09.032. View

Pompili M, Rihmer Z, Akiskal H, Amore M, Gonda X, Innamorati M . Temperaments mediate suicide risk and psychopathology among patients with bipolar disorders. Compr Psychiatry. 2011; 53(3):280-5. DOI: 10.1016/j.comppsych.2011.04.004. View

Montgomery S, Asberg M . A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134:382-9. DOI: 10.1192/bjp.134.4.382. View

Duncan W, Sarasso S, Ferrarelli F, Selter J, Riedner B, Hejazi N . Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol. 2012; 16(2):301-11. PMC: 3510337. DOI: 10.1017/S1461145712000545. View

Vande Voort J, Ballard E, Luckenbaugh D, Bernert R, Richards E, Niciu M . Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder. J Clin Psychiatry. 2016; 78(8):1068-1074. PMC: 5641476. DOI: 10.4088/JCP.15m10440. View

10.

Wilkowska A, Wiglusz M, Arciszewska-Leszczuk A, Galuszko-Wegielnik M, Cubala W . Anhedonia in bipolar depression treated with ketamine. Bipolar Disord. 2024; 26(4):356-363. DOI: 10.1111/bdi.13409. View

11.

Rodrigues N, McIntyre R, Lipsitz O, Cha D, Cao B, Lee Y . Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?. J Sleep Res. 2021; 31(1):e13400. DOI: 10.1111/jsr.13400. View

12.

Duncan Jr W, Ballard E, Zarate C . Ketamine-Induced Glutamatergic Mechanisms of Sleep and Wakefulness: Insights for Developing Novel Treatments for Disturbed Sleep and Mood. Handb Exp Pharmacol. 2017; 253:337-358. PMC: 5866161. DOI: 10.1007/164_2017_51. View

13.

Cuthbert B . Research Domain Criteria: toward future psychiatric nosologies. Dialogues Clin Neurosci. 2015; 17(1):89-97. PMC: 4421905. View

14.

Ionescu D, Fu D, Qiu X, Lane R, Lim P, Kasper S . Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). Int J Neuropsychopharmacol. 2020; 24(1):22-31. PMC: 7816667. DOI: 10.1093/ijnp/pyaa068. View

15.

Slupski J, Cubala W, Gorska N, Slupska A, Galuszko-Wegielnik M . Copper and anti-anhedonic effect of ketamine in treatment-resistant depression. Med Hypotheses. 2020; 144:110268. DOI: 10.1016/j.mehy.2020.110268. View

16.

Trivedi M, Rush A, Ibrahim H, Carmody T, Biggs M, Suppes T . The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a.... Psychol Med. 2004; 34(1):73-82. DOI: 10.1017/s0033291703001107. View

17.

Kwasny A, Wlodarczyk A, Ogonowski D, Cubala W . Effect of Ketamine on Sleep in Treatment-Resistant Depression: A Systematic Review. Pharmaceuticals (Basel). 2023; 16(4). PMC: 10143949. DOI: 10.3390/ph16040568. View

18.

Ferrari A, Charlson F, Norman R, Patten S, Freedman G, Murray C . Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013; 10(11):e1001547. PMC: 3818162. DOI: 10.1371/journal.pmed.1001547. View

19.

Kwasny A, Wlodarczyk A, Dywel A, Szarmach J, Strandberg O, Cubala W . Residual insomnia in major depressive disorder: a systematic review. Front Psychiatry. 2023; 14:1190415. PMC: 10312086. DOI: 10.3389/fpsyt.2023.1190415. View

20.

Serafini G, Adavastro G, Canepa G, Capobianco L, Conigliaro C, Pittaluga F . Abnormalities in Kynurenine Pathway Metabolism in Treatment-Resistant Depression and Suicidality: A Systematic Review. CNS Neurol Disord Drug Targets. 2017; 16(4):440-453. DOI: 10.2174/1871527316666170413110605. View